Clinical Trials · NCT07218354
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- VA Office of Research and Development
- Enrollment
- 622
- Start date
- Jul 2026
- Locations
- 1 site, United States
- Primary endpoint
- Two-level reduction in the World Health Organization (WHO) risk drinking level